نتائج البحث

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.

• Authors : Stein A; University Medical Centre Hamburg-Eppendorf, Martinistrasse 52, Hamburg 20246, Germany.; Atanackovic D

Subjects: Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*administration & dosage ; Bevacizumab/Bevacizumab/Bevacizumab/*administration & dosage FOLFOXIRI protocol

• Source: British journal of cancer [Br J Cancer] 2015 Sep 15; Vol. 113 (6), pp. 872-7. Date of Electronic Publication: 2015 Sep 03.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited

تفاصيل العنوان

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.

• Authors : Beije, N¹; Kraan, J¹; Taal, W²

• Source: British Journal of Cancer. 7/14/2015, Vol. 113 Issue 2, p226-231. 6p. 3 Charts, 1 Graph.

تفاصيل العنوان

Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.

• Authors : Weickhardt, A J¹; Williams, D S²; Lee, C K³

• Source: British Journal of Cancer. 6/30/2015, Vol. 113 Issue 1, p37-45. 9p.

تفاصيل العنوان

Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial.

• Authors : Verstraete, M¹; Debucquoy, A¹; Dekervel, J²

• Source: British Journal of Cancer. 4/14/2015, Vol. 112 Issue 8, p1314-1325. 12p. 1 Diagram, 4 Charts, 3 Graphs.

تفاصيل العنوان

Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer.

• Authors : Price, T J¹; Bruhn, M A²; Lee, C K³

• Source: British Journal of Cancer. 3/17/2015, Vol. 112 Issue 6, p963-970. 8p.

تفاصيل العنوان

Does the cancer drugs fund lead to faster uptake of cost-effective drugs? A time-trend analysis comparing England and Wales.

• Authors : Chamberlain, C¹; Collin, S M¹; Stephens, P²

• Source: British Journal of Cancer. 10/28/2014, Vol. 111 Issue 9, p1693-1702. 10p. 3 Charts, 5 Graphs.

تفاصيل العنوان

Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.

• Authors : Schneider, B P¹; Li, L²; Shen, F¹

• Source: British Journal of Cancer. 9/9/2014, Vol. 111 Issue 6, p1241-1248. 8p. 2 Diagrams, 2 Charts, 2 Graphs.

تفاصيل العنوان

First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study.

• Authors : Feliu, J¹; Salud, A²; Safont, M J³

• Source: British Journal of Cancer. 7/15/2014, Vol. 111 Issue 2, p241-248. 8p. 6 Charts, 2 Graphs.

تفاصيل العنوان

Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI.

• Authors : Guo J; Department of Diagnostic Imaging, St Jude Children's Research Hospital, 262 Danny Thomas Place, Mail Stop 220, Memphis, TN 38105-3678, USA.; Glass JO

Subjects: Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*therapeutic use ; Bevacizumab/Bevacizumab/Bevacizumab/*therapeutic use ; Osteosarcoma/Osteosarcoma/Osteosarcoma/*drug therapy

• Source: British journal of cancer [Br J Cancer] 2015 Nov 03; Vol. 113 (9), pp. 1282-8. Date of Electronic Publication: 2015 Oct 13.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited

تفاصيل العنوان

A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma.

• Authors : Jobard E; Centre de RMN à Très Hauts Champs, Institut des Sciences Analytiques (CNRS/ENS Lyon/UCB Lyon 1), Université de Lyon, 69100 Villeurbanne, France.; Université de Lyon, Centre Léon Bérard, 69008 Lyon, France.

Subjects: Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*therapeutic use ; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; Bevacizumab/Bevacizumab/Bevacizumab/*therapeutic use

• Source: British journal of cancer [Br J Cancer] 2015 Oct 20; Vol. 113 (8), pp. 1148-57. Date of Electronic Publication: 2015 Sep 15.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited

تفاصيل العنوان